| Non-small cell lung cancer (NSCLC) patients with and without response to PD-I immunotherapy have different diversity and composition of gut microbiota. |
| The relative abundances of Escherichia-Shigella, Akkermansia and Olsenella might have contributed to the different composition of gut microbiota. |
| Escherichia-Shigella and Akkermansia might have specific effects on the PD-1 inhibitory immunotherapy for NSCLC, and a possible association with interleukin-12 (IL-12) and interferon gamma (IFN-γ). |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.